Canada Markets closed
  • S&P/TSX

    20,621.39
    -436.81 (-2.07%)
     
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • DOW

    34,265.37
    -450.03 (-1.30%)
     
  • CAD/USD

    0.7947
    -0.0052 (-0.6517%)
     
  • CRUDE OIL

    84.83
    -0.72 (-0.84%)
     
  • BTC-CAD

    44,959.30
    -3,386.34 (-7.00%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • GOLD FUTURES

    1,836.10
    -6.50 (-0.35%)
     
  • RUSSELL 2000

    1,987.92
    -36.12 (-1.78%)
     
  • 10-Yr Bond

    1.7470
    -0.0860 (-4.69%)
     
  • NASDAQ

    13,768.92
    -385.08 (-2.72%)
     
  • VOLATILITY

    28.85
    +3.26 (+12.74%)
     
  • FTSE

    7,494.13
    -90.88 (-1.20%)
     
  • NIKKEI 225

    27,522.26
    -250.64 (-0.90%)
     
  • CAD/EUR

    0.7001
    -0.0066 (-0.93%)
     

India's Biocon in talks with Mylan to merge biosimilar businesses - Moneycontrol

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • BIOCON.NS
  • VTRS

BENGALURU, Dec 9 (Reuters) - Indian drugmaker Biocon Ltd is in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, financial news website Moneycontrol reported https://bit.ly/3dxe54j on Thursday, citing sources with direct knowledge of the matter.

Biocon will seek to hold a controlling majority stake in the merged entity and the companies will also look for an initial public offering (IPO) for the entity post-merger in which they will seek a valuation of over $10 billion, the report said.

Biocon and Viatris Inc, the company which was formed after combining Mylan with Pfizer Inc's off-patent branded drugs business, did not immediately respond to Reuters' requests for comment.

Biocon's biosimilar business, Biocon Biologics, and Viatris already have an extensive collaboration agreement under which they develop, manufacture and commercialise a broad portfolio of biosimilars and diabetes generic drugs including insulin injection Semglee.

In September, Biocon said the biosimilar unit will sell a 15% stake to a Serum Institute of India subsidiary for access to millions of vaccine doses, including COVID-19 shots. The deal valued Biocon Biologics at about $4.9 billion.

Biocon Biologics has also raised capital through several rounds this year and last year from high-profile names such as Abu Dhabi-based ADQ, Goldman Sachs and Tata Capital Growth Fund.

Shares of Biocon were down about 2% as of 0520 GMT in a weak Mumbai market.

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Rashmi Aich)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting